Inhibitor development in correlation to factor VIII genotypes.
about
Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational ModificationsHelper-dependent adenoviral gene therapy mediates long-term correction of the clotting defect in the canine hemophilia A model.HLA-DR-restricted T-cell responses to factor VIII epitopes in a mild haemophilia A family with missense substitution A2201P.Validity of assessing inhibitor development in haemophilia PUPs using registry data: the EUHASS project.The intron-22-inverted F8 locus permits factor VIII synthesis: explanation for low inhibitor risk and a role for pharmacogenomicsA case-control study reveals immunoregulatory gene haplotypes that influence inhibitor risk in severe haemophilia A.Specific and global coagulation tests in patients with mild haemophilia A with a double mutation (Glu113Asp, Arg593Cys).Case studies: orthopaedic surgery in adult patients with haemophilia A with inhibitors.Optimal haemophilia care versus the reality.F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.New treatments in hemophilia: insights for the clinician.The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.Genetic risk factors for inhibitors to factors VIII and IX.Mild/moderate haemophilia A: new insights into molecular mechanisms and inhibitor development.Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014.Development of inhibitory antibodies to therapeutic factor VIII in severe hemophilia A is associated with microsatellite polymorphisms in the HMOX1 promoter.Severe Hemophilia A in a Male Old English Sheep Dog with a C→T Transition that Created a Premature Stop Codon in Factor VIII.Violating the theory of single gene-single disorder: inhibitor development in hemophiliaCoagulation disorders and inhibitors of coagulation in children from Mansoura, Egypt.A close insight to factor VIII inhibitor in the congenital hemophilia A.A Polymorphism in the IL-5 Gene is Associated with Inhibitor Development in Severe Hemophilia A PatientsManaging haemophilia for life: 4th Haemophilia Global Summit.An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan.Low incidence of factor VIII inhibitors in previously untreated patients during prophylaxis, on-demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical study.Identification and characterization of an adenine to guanine transition within intron 10 of the factor VIII gene as a causative mutation in a patient with mild haemophilia A.Identification of mutations in the F8 and F9 gene in families with haemophilia using targeted high-throughput sequencing.Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.Expression studies of mutant factor VIII alleles with premature termination codons with regard to inhibitor formation.IgE-mediated anaphylactic reaction to purified and recombinant factor VIII in a patient with severe haemophilia A.The correlation between gene mutations and inhibitor development in patients with haemophilia A in southern Iran.Factor VIII inhibitory antibody in a patient with combined factor V/factor VIII deficiency.Attitudes towards and beliefs about genetic testing in the haemophilia community: a qualitative study.The natural history of mild haemophilia: a 30-year single centre experience.A large deletion due to a new mutation (intron 13/exon 23) in a sporadic case of severe hemophilia A.Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis.Risk factors associated with inhibitor development in Chinese patients with haemophilia B.Profiling of differentially expressed genes in haemophilia A with inhibitor.Inhibitor incidence after intensive FVIII replacement for surgery in mild and moderate haemophilia A: a prospective national study in the Netherlands.Analysis of mRNA in hemophilia A patients with undetectable mutations reveals normal splicing in the factor VIII gene.A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model.
P2860
Q26738810-F153660E-1138-483B-A90A-33D62016A8B6Q33371228-E5C38839-B0FD-4093-A1C7-2A73D630C2F4Q33910694-0E6241E2-A33A-42BD-91BC-862B378A9066Q34063824-FFAB3B0E-97A6-4D21-A7E3-B0D94F63C4F3Q34876672-A42F0942-B645-4203-A732-0C5E7D679536Q35061778-C6BBB60C-9126-4EBB-9F81-CA961154436DQ36220085-E52CE50B-987E-4DBF-929A-BD015D16561AQ36283856-CDA980C6-43F8-480C-90C0-A35F5526349CQ36399847-C5B9D152-26A0-467C-8EB0-21696FCE92F4Q36463399-821E9CE5-6B58-4CD9-A990-9BE2FA8160BDQ36612681-3FE55E54-441F-407D-AEF4-341229980F13Q36628311-3AA0E4B3-4D1A-43E0-BAD1-1AEA99AC734FQ36661811-6FBFA416-0D97-4690-8001-B0DDB8E202A4Q37176534-3A12182F-987A-4D02-8419-55D57A433560Q37185097-00D4F3CD-5DF9-42B3-9BE2-41F4673829B2Q37212741-9EE7F28D-005A-4F11-9603-6EDCF11085AAQ37354951-43ED361B-C670-40EC-8695-3151A12964B9Q38397087-B5568CB2-91AF-4B2E-8AE5-FA545D46CE5EQ38855974-3B4BCB22-6B07-431B-BAAF-180C9C1E3CB4Q38883211-A1493491-6401-4C7B-8641-C0613D140D9BQ38914615-2C2EF6FA-CA4D-4470-B0D8-D3F409FEC8AFQ44122887-D9079A6A-2BB1-4A8D-AC4F-703B51581CD6Q44296354-135C090E-061D-440F-AB4D-8D1734BAC435Q44746723-3AC2C06C-4565-4876-989E-0CEABA1D1274Q44846549-FD5215DB-818B-4F39-A621-2414739EA07BQ45855110-17B39F74-92A8-4EE3-AB6F-7EC6359EFE6DQ45856064-DAF538D5-26AA-4899-AC34-73AEDCEEF730Q45863066-620249FA-9059-48F4-931C-CBE73962E850Q45864945-3BDD86D2-F464-40B9-B4B4-B345BD70FEDDQ45867984-242C49DD-C5E3-4EFE-B348-81F2F65D3C84Q45870991-CAF71540-49BF-49A6-812C-6252FE4B74D4Q45871296-E6D0D709-58E7-4AF3-9823-8F0EC09A3A03Q45871908-CAA3F748-A480-49C0-B63A-4AEAF1F531E9Q45873103-30057133-AE3B-4293-81F2-DED439085667Q45873688-02F780BF-5731-4DC7-94B1-8B01589563B9Q45875494-EE841F2D-6149-4C10-8242-59FF0E985C1DQ45875915-D4759D03-60F4-4D84-A869-0CDC374DE2F8Q45878830-9DB79467-FC18-4C1C-99F7-E89EEE527701Q45880854-9CF9A1F1-B26E-4DF1-A9DB-024E4B038CC7Q45882197-3E92162C-8376-467D-B24A-C2EE970D8A5F
P2860
Inhibitor development in correlation to factor VIII genotypes.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Inhibitor development in correlation to factor VIII genotypes.
@ast
Inhibitor development in correlation to factor VIII genotypes.
@en
Inhibitor development in correlation to factor VIII genotypes.
@nl
type
label
Inhibitor development in correlation to factor VIII genotypes.
@ast
Inhibitor development in correlation to factor VIII genotypes.
@en
Inhibitor development in correlation to factor VIII genotypes.
@nl
prefLabel
Inhibitor development in correlation to factor VIII genotypes.
@ast
Inhibitor development in correlation to factor VIII genotypes.
@en
Inhibitor development in correlation to factor VIII genotypes.
@nl
P2093
P2860
P1433
P1476
Inhibitor development in correlation to factor VIII genotypes.
@en
P2093
El-Maarri O
Oldenburg J
P2860
P356
10.1046/J.1351-8216.2001.00134.X
P478
P577
2002-03-01T00:00:00Z